ARVN
Arvinas, Inc.·Healthcare
8.85
0.785%(−0.07)
Close PriceLast Updated: — ET
52W L: $6.0652W H: $14.51
ARVN NEWS
globenewswire.com
May 18
Arvinas Employees Give Back During Company-wide Impact Day
NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that employees across Connecticut, in the Greater Boston area, and around the country, took part in the Company's fourth Arvinas Impact Day this past Friday. This company-wide day of service brings employees together to give back to their communities through volunteer activities that will make a meaningful difference across the Greater New Haven area and beyond.
benzinga.com
May 13
These Analysts Increase Their Forecasts On Arvinas After Q1 Results
Arvinas Inc (NASDAQ:ARVN) reported downbeat results for the first quarter on Tuesday.
seekingalpha.com
May 12
Arvinas, Inc. (ARVN) Q1 2026 Earnings Call Transcript
Arvinas, Inc. (ARVN) Q1 2026 Earnings Call Transcript
benzinga.com
May 12
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock is trading higher on Tuesday as the company is entering an exclusive global licensing agreement with Arvinas Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) for its oral PROTAC drug, VEPPANU (vepdegestrant).
marketbeat.com
May 12
Arvinas Q1 Earnings Call Highlights
Arvinas NASDAQ: ARVN said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline focused on targeted protein degradation.
zacks.com
May 12
Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to earnings of $1.14 per share a year ago.
